TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
January 29, 2024 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
Autism Spectrum Disorders Market Research Report by Drug, Product Type, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
January 11, 2023 06:09 ET
|
ReportLinker
New York, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Autism Spectrum Disorders Market Research Report by Drug, Product Type, Distribution, Region -...
Saniona AB’s Nomination Committee for the Annual General Meeting 2023
November 25, 2022 09:30 ET
|
Saniona AB
PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. ...
Saniona publicerar sin delårsrapport för det tredje kvartalet 2022
November 17, 2022 02:00 ET
|
Saniona AB
Q3 2022 (Q3 2021)Jan–sep 2022 (jan–sep 2021)Intäkter uppgick till 2,4 MSEK (2,3 M)Intäkter uppgick till 12,0 MSEK (7,6 M)Rörelseresultat uppgick till 21,8 MSEK (-88,2 M)Periodens resultat uppgick...
Saniona publishes its interim report for the third quarter of 2022
November 17, 2022 02:00 ET
|
Saniona AB
Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net...
Sanionas antiinflammatoriska och antifibrotiska kandidat SAN903 är redo för klinisk prövning
November 03, 2022 03:00 ET
|
Saniona AB
PRESSMEDDELANDE 3 november 2022 Den prekliniska utvecklingen av SAN903 har slutförts och övriga krav för klinisk utveckling är uppfylldaMöjlig first-in-class-substans öppnar för ett nytt...
Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies
November 03, 2022 03:00 ET
|
Saniona AB
PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment...
Sanionas kassa beräknas räcka längre efter ändring av låneavtalet med Formue Nord
September 30, 2022 06:30 ET
|
Saniona AB
PRESSMEDDELANDE 30 september 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att Saniona har kommit överens med Formue Nord Fokus A/S (Formue Nord) om...
Saniona extends runway and amends loan agreement with Formue Nord
September 30, 2022 06:30 ET
|
Saniona AB
PRESS RELEASE September 30, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that Saniona and Formue Nord Fokus A/S (Formue Nord) have agreed to the change the...
Candel Therapeutics Announces Two Executive Leadership Appointments
September 07, 2022 08:00 ET
|
Candel Therapeutics
Jason A. Amello joins Candel as Chief Financial OfficerGarrett Nichols, MD, MS, joins Candel as Chief Medical Officer NEEDHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc....